Clinical trials: Gram-negative Bacterial Infection
Latent Tuberculosis, Latent Tuberculosis Bacteriology and Histology Unknown
Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis
This is a Phase I, open-label, dose-escalation study with three study groups. This study will be conducted in 25 HIV negative subjects, 17 of whom will have Latent Tuberculosis Infection (LTBI) and 8 of whom will not have LTBI at…
- Trial name
- NCT01967134
- Testing
- H56:IC31
- Where
- South Africa
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Aeras
Cholera
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200
The purpose of this study is to compare the safety and immunogenicity of a single dose of the PXVX0200 live cholera vaccine versus placebo in volunteers (Vaccinees) and whether PXVX0200, which is a live attenuated bacteria, can…
- Trial name
- NCT01585181
- Testing
- PXVX0200
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Whooping Cough
Viaskin Pertussis Vaccine Trial
The study is a Phase I, first in human, monocenter study, aiming at assessing the safety and immunogenicity of a genetically detoxified pertussis toxin (PT) when administered via the cutaneous route with Viaskin patches to…
- Trial name
- NCT03035370
- Testing
- Viaskin PT 25 mcg, Viaskin PT 50 mcg, Boostrix™
- Where
- Switzerland
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- DBV Technologies
Southern Tick-Associated Rash Illness
Investigation of Southern Tick-Associated Rash Illness (STARI)
This study will evaluate blood and tissue samples for a condition called Southern Tick-Associated Rash Illness (STARI). This is a skin rash resembling erythema migrans, the rash found in people infected with Lyme disease.
- Trial name
- NCT00358761
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bacterial Infections, Bone Diseases, Infectious
Fosfomycin I.v. for Treatment of Severely Infected Patients
The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin…
- Conditions
- Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
- Trial name
- FORTRESS (NCT02979951)
- Where
- 50 sites in Austria, Germany and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Infectopharm Arzneimittel GmbH
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related…
- Trial name
- NCT04980872
- Testing
- Miransertib
- Where
- 11 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV, Chlamydia
National Rapid TLC: Testing and Linkage to Care
The goal of this cross-sectional study is to learn if the GeneXpert system is a practical system for HIV and STBBI testing in community-based organizations and health clinics.
- Conditions
- HIV, Chlamydia, Gonorrhea, HCV
- Trial name
- NCT07730801
- Testing
- Xpert® HIV-1 Qual XC
- Where
- 2 sites in Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Tuberculosis
A Study of MVA85A in Healthy Infants
This was a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity and efficacy of MVA85A/AERAS-485 in Bacillus Calmette-Guérin (BCG) vaccinated infants without tuberculosis or HIV infection.
- Trial name
- NCT00953927
- Testing
- MVA85A/AERAS-485, Candida Skin Test Antigen
- Where
- 3 sites in South Africa
- Volunteers
- 2,797 people, healthy volunteers welcome
- Sponsor
- Aeras
Diphtheria, Tetanus
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease
This is a randomized cross-sectional study of the Swedish population. Blood samples will be collected from a subpopulation in order to estimate the age specific sero-prevalence of the Swedish population for diseases included in…
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- Sero 2007 (NCT00932269)
- Where
- Sweden
- Volunteers
- 5,400 people, healthy volunteers welcome
- Sponsor
- Swedish Institute for Infectious Disease Control
Diphtheria, Tetanus
Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS
The objective of this study is to assess the immunogenicity and safety of the DTaP-IPV combination vaccine compared with those of separate DTaP and IPV vaccines administered to healthy infants at 2, 4, and 6 months of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- Venus (NCT02458183)
- Testing
- DTaP-IPV combination vaccine, DTaP vaccine and IPV vaccine
- Where
- 20 sites in South Korea, Thailand
- Volunteers
- 476 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Cystic Fibrosis, Infection
Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo
Our data indicate that the CFTR-molecule functions as a transporter for sphingosine-1-phosphate and sphingosine or regulates the uptake of these sphingolipids by epithelial cells.
- Conditions
- Cystic Fibrosis, Infection, Pseudomonas Aeruginosa
- Trial name
- NCT00515229
- Testing
- amitriptyline
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- University Hospital Tuebingen
Yaws
Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication
The current principle of yaws eradication (the Morges strategy) is based on single round mass drug administration (MDA) of azithromycin (AZI) called total community treatment (TCT) followed by targeted treatment of active cases…
- Trial name
- NCT03490123
- Testing
- R1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin
- Where
- Papua New Guinea
- Volunteers
- 56,000 people, healthy volunteers welcome
- Sponsor
- Lihir Medical Centre
Escherichia Coli Diarrhea
Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh
The purpose of this study is to determine if the ETEC vaccine ETVAX with and without dmLT adjuvant is safe and immunogenic in adults, children, toddlers and infants in Bangladesh.
- Trial name
- ETVAX/dmLT (NCT02531802)
- Testing
- ETVAX, dmLT, Bicarbonate Buffer
- Where
- Bangladesh
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- PATH
Chlamydia
Home-sampling in Partner Notification of Chlamydia
Though partner notification is mandatory to perform of Chlamydia trachomatis infected individuals in Sweden, there was a 10-15% annually increase of reported cases between 1997 and 2007 indicating that partner notification may…
- Trial name
- NCT01596946
- Testing
- Contact tracing mode test at clinic, Self-sampling at home - Sent Test Kit
- Where
- Sweden
- Volunteers
- 633 people, healthy volunteers welcome
- Sponsor
- Ostergotland County Council, Sweden
Typhoid Fever
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants
This phase 2 trial is aimed to obtain information on the safety and immunogenicity of the Vi-CRM197 in subjects from various age groups in India and Pakistan where Typhoid Fever is highly endemic and an efficacious vaccine…
- Trial name
- NCT01229176
- Testing
- Vi-CRM197 vaccine, Vi Polysaccharide (PS) vaccine, Pneumococcal conjugate vaccine
- Where
- 2 sites in India, Pakistan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Novartis
Pertussis
Pertussis Immunization During Pregnancy: Effect in Term and Preterm Infants
Young infants are most vulnerable to severe disease and even death when infected with Bordetella Pertussis. The current vaccines and vaccination programs do not guarantee protection of neonates.
- Trial name
- MAMA (NCT02511327)
- Testing
- Infant pertussis vaccination
- Where
- Belgium
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Helicobacter Infections, Gastritis
Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection
Proton pump inhibitors (PPIs) are mainly metabolized in the liver by CYP2C19, one of the cytochrome P450 isoenzymes, which shows a genetic polymorphism associated with enzyme activities. The most essential role of a PPI in H.
- Conditions
- Helicobacter Infections, Gastritis, Gastric Ulcer, Duodenal Ulcer
- Trial name
- NCT00197418
- Testing
- rabeprazole, amoxicillin, clarithromycin, metronidazole
- Where
- Japan
- Sponsor
- Hamamatsu University
Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis
Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers
In the early years of the HIV epidemic in Africa, female sex workers (FSWs) were identified as a high-prevalence, high-incidence, core group among whom the extraordinary prevalence of other sexually transmitted infections (STIs)…
- Conditions
- Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis, HIV
- Trial name
- NCT01329588
- Testing
- Monthly antibiotic
- Where
- Benin
- Volunteers
- 636 people
- Sponsor
- CHU de Quebec-Universite Laval
Haemophilus Influenzae Type b, Diphtheria
Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine
To assess the safety and reactogenicity of the DTPa-HBV-IPV/Hib vaccine and DTPa-IPV/Hib vaccine. This DTPa-IPV/Hib vaccine given at 3 and 4 months of age is co-administered with GSK Biologicals' rotavirus vaccine or Placebo.
- Conditions
- Haemophilus Influenzae Type b, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00325143
- Testing
- DTPa-HBV-IPV/Hib, DTPa-IPV/Hib vaccine
- Where
- 3 sites in Singapore
- Volunteers
- 702 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pertussis
2-year Follow-up After a Single Dose Acellular Pertussis Vaccination
In July 2015-November 2016, a phase II/III randomized, observer-blind,controlled study of two acellular Pertussis vaccines (aP standalone and TdaP combined vaccined) manufactured by BioNet-Asia Co., Ltd.
- Trial name
- NCT04113655
- Testing
- Pertagen (aP BioNet), Boostagen (TdaP BioNet), Adacel
- Where
- 2 sites in Thailand
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Mahidol University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.